Post by
Noteable on Mar 17, 2023 11:49am
TIGIT class of checkpoint inhibitors fails with Keytruda
March 17, 2023 - Merck's (MSD) co-formulation of Keytruda and anti-TIGIT therapy vibostolimab did not improve progression-free survival compared to chemotherapy alone in patients with metastatic non-small cell lung cancer that had previously been treated with immunotherapy and platinum-doublet chemotherapy.
This failure suggests that the hypoxic TME was unable to be remodeled nor could the innate system be "primed" for Merck's anti-PD-1 Keytruda to work.
These results add further credibility to the affect of ONCY's pelareorep on remodeling the TME and pelareorep's ability to "prime" both the innate and adaptive immune systems prior to the addition of a PD-(L)1 checkpoint inhibitor like Keytruda or Tecentriq or Bavencio, for example.
https://www.fiercebiotech.com/biotech/merck-tacks-another-loss-anti-tigits-company-not-losing-hope-larger-strategy
Comment by
fox7mf on Mar 17, 2023 12:07pm
Roche & Merck may be pursuing the acquisition of Oncy just a tad bit more forcibly at the moment. We'll see what Roche's new CEO has first on the M&A docket soon.
Comment by
Azzak34 on Jun 09, 2023 4:41pm
Noteable would you agree with the idiot below that Pela clearly didn't do well enough woth paclitaxel and big pharma must have walked away?
Comment by
Noteable on Jan 10, 2024 12:42pm
January 10, 2024 - Coherus BioSciences pulls out of TIGIT. https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-ord-shs?postid=35819574
Comment by
13X2413 on Jun 09, 2023 6:19pm
I like your positivity, but it appears that the big investors aren't buying what the company is selling. Way too much selling for something that's supposed to look promising. The results don't seem to be impressing people. Need something from the company to prop this up. $1 land is way to close now. Like $3 territory much better. Much easier to sleep.
Comment by
westcoast1000 on Jun 09, 2023 6:30pm
You have no way of knowing what big investors think, nor what they want to buy from the company. You have no way of knowing whether the results are impressing people, except to look at the results, which are impressive. The share price will stay low until progress is announced.
Comment by
Noteable on Jun 09, 2023 4:42pm
From these developments one can see that Big Pharma is having significant difficulty in finding novel cancer therapies, at the same time that Big Pharma is faced with a looming patent cliff. We also see that Roche has bet heavily on the TIGIT class of checkpoint inhibitors.
Comment by
Noteable on May 13, 2024 11:10am
May 13, 2024 - Merck ends Phase III Anti-Tigit + Keytruda melanoma study with high dropouts. The late-stage study was evaluating vibostolimab as an adjuvant treatment to Keytruda in patients with resected, high-risk melanoma. https://www.biospace.com/article/merck-halts-phase-iii-anti-tigit-keytruda-skin-cancer-study-with-high-dropouts-/